KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Investment Securities (2016 - 2025)

Neogenomics (NEO) has disclosed Gains from Investment Securities for 16 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 150.89% year-over-year to $57000.0, compared with a TTM value of $515000.0 through Dec 2025, up 148.79%, and an annual FY2025 reading of $515000.0, up 148.79% over the prior year.
  • Gains from Investment Securities was $57000.0 for Q4 2025 at Neogenomics, down from $458000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $458000.0 in Q2 2025 and bottomed at -$112000.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $87500.0, with a median of $72000.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities plummeted 2550.0% in 2021, then skyrocketed 2700.0% in 2022.
  • Year by year, Gains from Investment Securities stood at $35000.0 in 2021, then fell by 28.57% to $25000.0 in 2022, then skyrocketed by 600.0% to $175000.0 in 2023, then tumbled by 164.0% to -$112000.0 in 2024, then surged by 150.89% to $57000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for NEO at $57000.0 in Q4 2025, $458000.0 in Q2 2025, and -$112000.0 in Q4 2024.